AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17557893 — intervention group
Group type: EXPERIMENTAL
Intervention: Newcomers criticizing an Internet community (Experiment 3)
Number of subjects: 411
Study 19902697 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video compact disc (VCD) and cataract information leaflets
Number of subjects: 463
Study 19902697 — intervention group
Group type: COMPARATOR
Intervention: Cataract information leaflets
Number of subjects: 463
Study 11979243 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg intravenously)
Number of subjects: 36
Study 11979243 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 36
Study 9469358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 20 mg/m2
Number of subjects: 241
Study 9469358 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin and vincristine (BV) combination
Number of subjects: 241
Study 9469358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 241
Study 7637156 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone infusion
Number of subjects: 26
Study 7637156 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (Control)
Number of subjects: 26
Study 2372037 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives containing 30 to 50 micrograms of ethinyl estradiol
Number of subjects: 28
Study 2372037 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy nonusers)
Number of subjects: 28
Study 480949 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) 5 mg orally t.i.d.
Number of subjects: 34
Study 480949 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) 5 mg orally t.i.d. + Chlorambucil (CB) 0.1‐‐0.2 mg/kg/day orally
Number of subjects: 34
Study 29999394 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mentalization-based Families and Carers Training and Support (5 sessions of 1.5-2 hours each)
Number of subjects: 56
Study 29999394 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 56
Study 29999394 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mentalization-based Families and Carers Training and Support
Number of subjects: 56
Study 27705069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 0
Study 25736355 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 0
Study 25736355 — intervention group
Group type: COMPARATOR
Intervention: IFX
Number of subjects: 0
Study 24158493 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 69
Study 24158493 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestant (xylometazoline hydrochloride, 0.05%)
Number of subjects: 69
Study 24158493 — intervention group
Group type: EXPERIMENTAL
Intervention: TLA with decongestant (lidocaine hydrochloride, 1% with xylometazoline hydrochloride, 0.05%)
Number of subjects: 69
Study 21258848 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive website (www.wiagesprek.nl) with five interactive modules aimed at increasing knowledge, self‐awareness, expectations, self‐efficacy, and active participation.
Number of subjects: 242
Study 21258848 — intervention group
Group type: COMPARATOR
Intervention: Control group directed to a 'sham' website with commonly available information only.
Number of subjects: 242
Study 21258848 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive website (www.wiagesprek.nl)
Number of subjects: 242
Study 19636665 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 degrees BOAD
Number of subjects: 179
Study 19636665 — intervention group
Group type: COMPARATOR
Intervention: 5 degrees BOAD
Number of subjects: 179
Study 17288611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 4% gel applied to the skin for 30 minutes
Number of subjects: 142
Study 17288611 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to the skin for 30 minutes
Number of subjects: 142
Study 17288611 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose administration (24% sucrose)
Number of subjects: 142
Study 17288611 — intervention group
Group type: EXPERIMENTAL
Intervention: Local skin reactions
Number of subjects: 142
Study 14671041 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line haemodiafiltration (HDF) using Helixone membrane
Number of subjects: 0
Study 14671041 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD) with Helixone membrane
Number of subjects: 0
Study 14671041 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line HDF using standard polysulphone membrane
Number of subjects: 0
Study 14671041 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis (HD) using polysulphone membrane
Number of subjects: 0
Study 11330878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 17
Study 9401083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (IDARA-C) plus idarubicin (IDA) and prednisone (PDN) during induction phase
Number of subjects: 73
Study 9401083 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (BMT)
Number of subjects: 73
Study 9401083 — intervention group
Group type: EXPERIMENTAL
Intervention: All enrolled children
Number of subjects: 73
Study 9401083 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 10 years at initial diagnosis
Number of subjects: 73
Study 9401083 — intervention group
Group type: EXPERIMENTAL
Intervention: First CR duration >= 12 months and WBC count at relapse < 20 x 10(9)/l
Number of subjects: 73
Study 9401083 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >= 10 years at initial diagnosis and WBC count at relapse >= 20 x 10(9)/l
Number of subjects: 73
Study 7525055 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) at a maximum tolerated dose of 1000 mg/m2, administered at 14-day intervals, supported by peripheral blood progenitors and filgrastim.
Number of subjects: 31
Study 7525055 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) at various dose levels: Level I (500 mg/m2), Level II (800 mg/m2), Level III (1200 mg/m2), Level IIIa (1000 mg/m2), and Level IV (1000 mg/m2) plus cyclophosphamide (CPA) at 1500 mg/m2.
Number of subjects: 31
Study 7525055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBDCA (1000 mg/m2) plus CPA (1500 mg/m2) in Level IV.
Number of subjects: 31
Study 7525055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA) at a dose of 3.0 g/m2, supported by filgrastim.
Number of subjects: 31
Study 7525055 — intervention group
Group type: EXPERIMENTAL
Intervention: CBDCA dose intensities for each dose level: I (185 mg/m2), II (328 mg/m2), III (567 mg/m2), IIIa (465 mg/m2), Level IV (468 mg/m2).
Number of subjects: 31
Study 3310924 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 ppm formaldehyde exposure for 40 min
Number of subjects: 15
Study 3310924 — intervention group
Group type: COMPARATOR
Intervention: Room air exposure
Number of subjects: 15
Study 31155650 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week amphotericin B plus flucytosine
Number of subjects: 236
Study 28742756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 342
Study 28742756 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Number of subjects: 342
Study 28742756 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 342
Study 25979307 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 1500 mg/day with aspirin 325 mg/day
Number of subjects: 99
Study 25979307 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day
Number of subjects: 99
Study 24061336 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based learning with 2 additional hours of tuition using human patient simulators.
Number of subjects: 0
Study 24061336 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving identical blood pressure measurement education without additional simulation.
Number of subjects: 0
Study 20538357 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for women
Number of subjects: 802
Study 19336644 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium L-lactate (6 tablets daily, 504 mg elemental magnesium)
Number of subjects: 50
Study 19336644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19336644 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium L-lactate
Number of subjects: 50
Study 17453221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal non‐moistened (dry) misoprostol (group A, n = 40)
Number of subjects: 81
Study 17453221 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol moistened with 3 ml of saline (group B, n = 41)
Number of subjects: 81
Study 17453221 — intervention group
Group type: COMPARATOR
Intervention: Comparison of delivery with first dose, delivery within 12 hours, and delivery within 24 hours
Number of subjects: 81
Study 15215808 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score developed from significant variables including age >65 years, heart rate >100 beats/min, history of diabetes mellitus, lateral electrocardiographic changes, and history of angiographically confirmed coronary artery disease.
Number of subjects: 4681
Study 15215808 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (B-type natriuretic peptide) added to the risk score.
Number of subjects: 4681
Study 11332163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg/d gluten (group A)
Number of subjects: 54
Study 11332163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/d gluten (group B)
Number of subjects: 54
Study 11332163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/d gluten (group B) after increasing dose from 0.2 g/kg/d
Number of subjects: 54
Study 11332163 — intervention group
Group type: COMPARATOR
Intervention: Control for AGA and EmA levels
Number of subjects: 54
Study 11477861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongqiao tablet (TQT)
Number of subjects: 96
Study 11477861 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 96
Study 8041413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 520
Study 8041413 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 520
Study 2646983 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 32
Study 2646983 — intervention group
Group type: COMPARATOR
Intervention: Chlormethiazole
Number of subjects: 32
Study 29602750 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sternal precautions (less restrictive)
Number of subjects: 72
Study 29602750 — intervention group
Group type: COMPARATOR
Intervention: Usual restrictive sternal precautions
Number of subjects: 72
Study 27167119 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief thermal sensitization (45°C for 3 min)
Number of subjects: 50
Study 27167119 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain detection threshold
Number of subjects: 50
Study 26205427 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants (≤34 weeks GA)
Number of subjects: 90
Study 26205427 — intervention group
Group type: COMPARATOR
Intervention: Term infants (≥38 weeks GA)
Number of subjects: 90
Study 23547660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg once daily
Number of subjects: 17000
Study 23547660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg once daily
Number of subjects: 17000
Study 23547660 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium HandiHaler 18 μg once daily
Number of subjects: 17000
Study 21923604 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-pull method of blood sampling from ports
Number of subjects: 62
Study 21923604 — intervention group
Group type: COMPARATOR
Intervention: Finger lancet puncture
Number of subjects: 62
Study 18333940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine transfusion (IUT) given to all survivors who were anaemic
Number of subjects: 19
Study 18333940 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive techniques
Number of subjects: 19
Study 18333940 — intervention group
Group type: EXPERIMENTAL
Intervention: Other management techniques
Number of subjects: 19
Study 16835556 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 12685617 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic nitrate treatment for 6 months after MI
Number of subjects: 59
Study 12685617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrate treatment)
Number of subjects: 59
Study 10099056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiazac (240 mg single dose)
Number of subjects: 23
Study 10099056 — intervention group
Group type: COMPARATOR
Intervention: Cardizem CD (240 mg single dose)
Number of subjects: 23
Study 10099056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiazac (240 mg steady-state)
Number of subjects: 23
Study 7656918 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I 20 micrograms kg-1 h-1
Number of subjects: 6
Study 7656918 — intervention group
Group type: COMPARATOR
Intervention: Insulin 0.5 mU kg-1 min-1
Number of subjects: 6
Study 2679397 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol mouth wash (4-5 times daily before and after treatment)
Number of subjects: 30
Study 2679397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no allopurinol mouth wash)
Number of subjects: 30
Study 998545 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets supplemented with lysine (1.8 g)
Number of subjects: 6
Study 998545 — intervention group
Group type: COMPARATOR
Intervention: Diets without additional lysine (1.2 g)
Number of subjects: 6
Study 998545 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets with 100% or 50% replacement of amino acids from rice and wheat
Number of subjects: 6
Study 31476260 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous valve repair plus medical treatment (n=152)
Number of subjects: 304
Study 31476260 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (n=152)
Number of subjects: 304
Study 28712941 — intervention group
Group type: EXPERIMENTAL
Intervention: GP2013-CVP
Number of subjects: 629
Study 28712941 — intervention group
Group type: COMPARATOR
Intervention: R-CVP
Number of subjects: 629
Study 23569308 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus zibotentan 10 mg/d
Number of subjects: 1052
Study 23569308 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus placebo
Number of subjects: 1052
Study 21982143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-wide computerised antimicrobial approval system (HCAAS)
Number of subjects: 3500
Study 21982143 — intervention group
Group type: EXPERIMENTAL
Intervention: HCAAS
Number of subjects: 3500
Study 18365222 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of 0.1 mg fentanyl + 5 ml bupivacaine 0.5%
Number of subjects: 564
Study 18365222 — intervention group
Group type: COMPARATOR
Intervention: Postoperative administration of 0.1 mg fentanyl + 5 ml bupivacaine 0.5%
Number of subjects: 564
Study 18365222 — intervention group
Group type: COMPARATOR
Intervention: Postoperative administration of 5 ml bupivacaine 0.5% alone
Number of subjects: 564
Study 17803345 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg/day
Number of subjects: 422
Study 17803345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 15465069 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy or antidepressant medications
Number of subjects: 14
Study 11396760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy with a 3% ethanolamine oleate solution (group 1, 18 patients)
Number of subjects: 36
Study 11396760 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of tissue adhesive N-butyl-2-cyanoacrylate (group 2, 18 patients)
Number of subjects: 36
Study 9849455 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus filgrastim
Number of subjects: 59
Study 9849455 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 59
Study 8006922 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA type diet (32/10:8:8)
Number of subjects: 160
Study 8006922 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoene-enriched diet (34/11:11:5)
Number of subjects: 160
Study 8006922 — intervention group
Group type: COMPARATOR
Intervention: Control diet (high in saturated fats) (35/14:10:4)
Number of subjects: 160
Study 8006922 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (30/12:8:3)
Number of subjects: 160
Study 2006655 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide or bendroflumethazide
Number of subjects: 1396
Study 2006655 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, nadolol, or captopril
Number of subjects: 1396
Study 598635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg orally
Number of subjects: 5
Study 598635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg sublingually
Number of subjects: 5
Study 598635 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate, 5 mg sublingually
Number of subjects: 5
Study 598635 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 40 mg orally
Number of subjects: 5
Study 598635 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 c. orally
Number of subjects: 5
Study 31402145 — intervention group
Group type: EXPERIMENTAL
Intervention: Current malaria
Number of subjects: 820
Study 31402145 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation (C-reactive protein >5 mg/L or α-1 acid glycoprotein >1 g/L)
Number of subjects: 820
Study 31402145 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 820
Study 31402145 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency (retinol <0.7 μmol/L)
Number of subjects: 820
Study 31402145 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional iron deficiency
Number of subjects: 820
Study 31402145 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia and ID in low malaria season
Number of subjects: 820
Study 28870407 — intervention group
Group type: COMPARATOR
Intervention: D2/3 receptor availability in striatal regions (including bilateral ventral pallidum/nucleus accumbens, right ventral caudate, and putamen)
Number of subjects: 23
Study 28870407 — intervention group
Group type: EXPERIMENTAL
Intervention: D2/3 receptor availability in the caudal portion of the ventral striatum (NAc/vPAL)
Number of subjects: 23
Study 28870407 — intervention group
Group type: EXPERIMENTAL
Intervention: D2/3 receptor availability in the rostral area of the ventral striatum
Number of subjects: 23
Study 28870407 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety and D2/3 receptor availability in the NAc/vPAL
Number of subjects: 23
Study 28870407 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-induced DA release in the bilateral NAc
Number of subjects: 23
Study 26251413 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioural therapy (RAFT) delivered by local rheumatology clinical teams, consisting of 6 sessions of 2 hours each (weeks 1-6) and a 1-hour consolidation session (week 14).
Number of subjects: 64
Study 26251413 — intervention group
Group type: COMPARATOR
Intervention: Usual care (fatigue self-management booklet, discussed for 5-6 minutes).
Number of subjects: 64
Study 26251413 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioural therapy (RAFT).
Number of subjects: 64
Study 23438931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention of sodium reduction
Number of subjects: 0
Study 23438931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention of weight loss
Number of subjects: 0
Study 23438931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sodium reduction and weight loss
Number of subjects: 0
Study 23438931 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study 22151943 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling
Number of subjects: 30
Study 22151943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of microneedling and 35% GA peels
Number of subjects: 30
Study 22151943 — intervention group
Group type: COMPARATOR
Intervention: Microneedling (Control Group)
Number of subjects: 30
Study 19187557 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquamin (2400 mg/d)
Number of subjects: 29
Study 19187557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16849756 — intervention group
Group type: EXPERIMENTAL
Intervention: Window therapy (various agents including ifosfamide, etoposide, doxorubicin, topoisomerase I poisons)
Number of subjects: 420
Study 16849756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide/topoisomerase II inhibitor trials
Number of subjects: 420
Study 16849756 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS‐III and ifosfamide/etoposide and ifosfamide/doxorubicin trials
Number of subjects: 420
Study 16849756 — intervention group
Group type: EXPERIMENTAL
Intervention: Window nonresponders
Number of subjects: 420
Study 16849756 — intervention group
Group type: COMPARATOR
Intervention: Window trials compared to IRS‐III
Number of subjects: 420
Study 16154241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol measles vaccine (10(3.58) CCID50/0.1 mL)
Number of subjects: 100
Study 16154241 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous measles vaccine (10(4.28) CCID50/0.5 mL)
Number of subjects: 100
Study 16154241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol measles vaccine
Number of subjects: 100
Study 16154241 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous measles vaccine
Number of subjects: 100
Study 14562673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenax stent (a-SiC:H coated)
Number of subjects: 497
Study 14562673 — intervention group
Group type: COMPARATOR
Intervention: Nir stent (stainless steel)
Number of subjects: 497
Study 10354255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse standing orders with comparative feedback and patient and clinician reminders
Number of subjects: 3502